(Q51313434)

3 April 2018

title

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. (English)

1 reference

3 April 2018

0 references

1 reference

1 reference

9

H Yki-Järvinen

1 reference

3 April 2018

2

H-U Häring

1 reference

3 April 2018

author name string

D D'Alessio

1

1 reference

3 April 2018

B Charbonnel

3

1 reference

3 April 2018

P de Pablos-Velasco

4

1 reference

3 April 2018

C Candelas

5

1 reference

3 April 2018

M-P Dain

6

1 reference

3 April 2018

M Vincent

7

1 reference

3 April 2018

V Pilorget

8

1 reference

3 April 2018

EAGLE Investigators

10

1 reference

3 April 2018

publication date

7 December 2014

1 reference

3 April 2018

Diabetes, Obesity and Metabolism

published in

1 reference

3 April 2018

volume

17

1 reference

3 April 2018

issue

2

1 reference

3 April 2018

page(s)

170-178

1 reference

3 April 2018

Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.

cites work

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes

21 January 2018

1 reference

Mechanisms linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.

21 January 2018

1 reference

Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people

21 January 2018

1 reference

Incretin-based therapies for type 2 diabetes mellitus

21 January 2018

1 reference

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL.

21 January 2018

1 reference

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

21 January 2018

1 reference

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials.

21 January 2018

1 reference

Dose-response effects of insulin glargine in type 2 diabetes

21 January 2018

1 reference

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia

21 January 2018

1 reference

Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials

21 January 2018

1 reference

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12406

1 reference

3 April 2018

PubMed ID

25359159

1 reference

3 April 2018